Brokerages Set Galapagos NV (NASDAQ:GLPG) PT at $30.75

Galapagos NV (NASDAQ:GLPG) has been assigned a consensus rating of “Reduce” from the seven research firms that are currently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating and five have given a hold rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $30.75.

Several analysts recently commented on GLPG shares. Leerink Partnrs upgraded shares of Galapagos to a “hold” rating in a research report on Monday, September 9th. Raymond James lowered shares of Galapagos from an “outperform” rating to a “market perform” rating in a research report on Friday, August 2nd. Royal Bank of Canada dropped their price target on shares of Galapagos from $32.00 to $30.00 and set a “sector perform” rating on the stock in a research report on Friday, November 1st. Leerink Partners started coverage on shares of Galapagos in a research report on Monday, September 9th. They set a “market perform” rating and a $24.00 price target on the stock. Finally, Kepler Capital Markets lowered shares of Galapagos from a “hold” rating to a “reduce” rating in a research report on Wednesday, November 20th.

Galapagos Price Performance

Shares of Galapagos stock opened at $26.90 on Friday. The firm has a fifty day moving average price of $28.55 and a 200 day moving average price of $27.48. Galapagos has a 1 year low of $24.16 and a 1 year high of $42.46.

Institutional Trading of Galapagos

Several institutional investors have recently modified their holdings of the stock. Erste Asset Management GmbH acquired a new stake in shares of Galapagos in the third quarter valued at about $410,000. Finepoint Capital LP boosted its position in Galapagos by 2.8% during the third quarter. Finepoint Capital LP now owns 557,762 shares of the biotechnology company’s stock worth $16,058,000 after acquiring an additional 15,000 shares during the last quarter. Crossmark Global Holdings Inc. acquired a new position in Galapagos during the third quarter worth about $1,077,000. QRG Capital Management Inc. acquired a new position in Galapagos during the third quarter worth about $247,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in Galapagos by 63.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 3,899 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 1,510 shares during the last quarter. Institutional investors and hedge funds own 32.46% of the company’s stock.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.